Brief: Arctic Bioscience H1 EBITDA Loss Of NOK 14.4 Million

Arctic Bioscience AS

25/08/2022 07:19

Aug 25 (Reuters) - Arctic Bioscience AS  ABSA.OL :
    * ARCTIC BIOSCIENCE - REVENUE GROWTH AND HRO350 PHASE IIB
CLINICAL
TRIAL ON TRACK
    * TOTAL REVENUE INCREASED 20 % Y/Y TO NOK 14,4 MILLION IN H1
2022,
FROM NOK 12 MILLION IN H1 2021
    * EBITDA OF NOK -14,4 MILLION IN H1 2022 (NOK -19,9 MILLION)
    * LIQUIDITY SITUATION AT END OF YEAR IS EXPECTED TO BE
STRONG, AND
SUFFICIENT TO HANDLE PHARMACEUTICAL PHASE IIB CLINICAL TRIAL
    * EXPECTS A POSITIVE DEVELOPMENT IN REVENUES DURING SECOND
HALF OF
2022, FORECASTING A 60-70 % Y/Y REVENUE GROWTH IN 2022
    * CLINICAL TRIAL APPLICATION IS EXPECTED TO BE SUBMITTED IN
Q3
2022, ALLOWING FIRST PATIENTS TO BE ENROLLED TO CLINICAL TRIAL
IN Q4 2022

Source text for Eikon:  ID:nWkr8hDdHK 
Further company coverage:  ABSA.OL 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))